Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2019 to Jun 2024
TKT Reports Third Quarter 2004 Financial Results
CAMBRIDGE, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) today announced its consolidated financial results for the
three and nine months ending September 30, 2004.
Total sales of Replagal(TM) (agalsidase alfa), TKT's enzyme replacement therapy
for Fabry disease, were approximately $19.5 million for the third quarter of
2004, which represents an increase of 28% over the same period in 2003 and 8%
over the $18.1 million recorded in the second quarter of 2004. For the nine
months ended September 30, 2004, Replagal sales totaled $54.9 million, compared
to sales of $41.7 million for the nine months ended September 30, 2003.
Net loss for the third quarter of 2004 was $18.8 million, or $0.54 per share,
compared to a net loss of $13.6 million, or $0.39 per share, for the same
period in 2003. For the nine months ended September 30, 2004, the net loss was
$53.2 million, or $1.53 per share, compared to $60.5 million, or $1.75 per
share, for the nine months ended September 30, 2003.
Costs of goods sold in the third quarter of 2004 totaled $3.4 million, or 17%
of product sales, compared to $2.8 million, or 18% of product sales, for the
corresponding quarter in 2003. For the nine months ended September 30, 2004,
cost of goods sold was $8.9 million compared to $11.0 million for the nine
months ended September 30, 2003.
Research and development expenses totaled $23.5 million in the third quarter of
2004, compared to $17.9 million for the same period in 2003. For the nine
months ended September 30, 2004, research and development expenses totaled
$65.7 million, compared to $55.7 million for the same period in 2003. The
increase in research and development expenses was primarily due to increased
clinical trial and manufacturing costs associated with iduronate-2- sulfatase
(I2S), enzyme replacement therapy for Hunter syndrome, and GA-GCB, enzyme
replacement therapy for Gaucher disease, as well as contract manufacturing
costs for Dynepo(TM) (epoeitin delta), TKT's Gene-Activated(R) erythropoietin
product for the treatment of anemia.
Selling, general and administrative expenses were $10.0 million in the third
quarter of 2004, compared to $7.3 million for the same period in 2003. For the
nine months ended September 30, 2004, SG&A was $30.9 million, compared to $25.9
million for the nine months ended September 30, 2003. The increase in SG&A
was primarily associated with increased sales costs, including incentive
compensation, at TKT Europe as well as costs incurred with the U.K. Dynepo
patent litigation.
At September 30, 2004, the company had cash and marketable securities of
approximately $222.8 million and long-term debt totaling $94 million.
"We are pleased with the continued growth of Replagal in Europe and the
progress we have made on our key business goals," said Michael J. Astrue,
President and Chief Executive Officer of TKT.
Program Highlights
Replagal for Fabry Disease
In October 2004, TKT completed the acquisition of the 20% minority interest in
TKT Europe-5S for $61 million in cash. With this purchase, TKT now owns 100%
of TKT Europe-5S.
I2S for Hunter Syndrome
In September 2004, TKT commenced its open-label extension study for I2S.
Patients who have completed twelve months of treatment in the pivotal clinical
trial, referred to as the AIM study (Assessment of I2S in MPS II) are eligible
to cross over into the extension study where all patients will receive I2S. The
company intends to report top-line results from the AIM study in the second
quarter of 2005. Also during the third quarter, TKT received fast track
designation for I2S from the U.S. Food and Drug Administration and a $300,000
grant from the Office of Orphan Drug Products to support the AIM study.
GA-GCB for Gaucher Disease
In July 2004, TKT closed enrollment in its Phase I/II clinical trial evaluating
GA-GCB in 12 patients. The trial is expected to conclude in the second
quarter of 2005 and the company expects to report top-line results during the
second half of 2005. In October 2004, Professor Ari Zimran, lead investigator
of the GA-GCB study, reported preliminary safety findings at the American
Society of Human Genetics Annual meeting. Professor Zimran's findings
demonstrated that IV infusions of GA-GCB were well-tolerated by patients in the
trial.
Dynepo for Anemia
During the quarter, TKT made the strategic decision to pursue a commercial
partnership for Dynepo in Europe. TKT also established a master contract
manufacturing agreement with Lonza in early August 2004. The company continues
to expect a European launch in late 2005 or early 2006. In addition, TKT
expects to announce top-line data from a pivotal trial evaluating Dynepo in
patients with anemia undergoing cancer chemotherapy in the first half of 2005
and, if the results are positive, to file an amendment to the Dynepo product
license and seek to expand the label. In October 2004, the House of Lords
affirmed an earlier U.K. decision in favor of TKT in its patent litigation
against Kirin-Amgen, Inc.
Upcoming Events
During the fourth quarter of 2004, TKT will present at the SG Cowen European
Health Care Conference being held in Geneva, Switzerland, November 16-17, 2004
and the Wachovia Capital Markets Ten for '05 Biotechnology Conference in New
York, New York, December 16, 2004. In addition, TKT is scheduled to present at
the JPMorgan Health Care Conference being held in San Francisco, California,
January 10-13, 2005.
Conference Call and Webcast
In connection with this announcement, TKT will host a conference call and live
webcast today, Tuesday, November 9, 2004, at 10:00 a.m. Eastern Standard Time
to discuss these results and the company's business generally. Participants may
access the call by dialing (719) 457-2618. The live webcast may be accessed in
the Investor Information section of TKT's website at http://www.tktx.com/.
A replay of this conference call will be available for two weeks beginning
today, November 9, 2004, at 1:00 p.m. Eastern Standard Time, by dialing (719)
457-0820 and using the access code 953576. A replay of the webcast will be
archived for one year on the TKT website in the Investor Information section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. Outside its
focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
Forward-looking Statements
This press release contains forward-looking statements including statements
regarding TKT's development of certain products, including Replagal, I2S,
GA-GCB and Dynepo, as well as statements containing the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should," "could,"
"will," "may," and similar expressions. There are a number of important factors
that could cause the company's actual results to differ materially from those
indicated by such forward-looking statements, including: whether any of the
company's products will achieve the commercial success anticipated by the
company; the timing of submissions to and decisions by regulatory authorities
regarding clinical trials and marketing and other applications; whether the
FDA, the EMEA and equivalent regulatory authorities will grant marketing
approval for the company's products on a timeline consistent with TKT's
expectations, or at all; whether TKT will be able to complete clinical trials
of its products on a timely basis; whether the results of clinical trials will
be consistent with the results of earlier clinical trials of the company's
products and warrant submission of applications for regulatory approval for
such products to the FDA and equivalent regulatory authorities; whether TKT and
its third party manufacturers will be able to complete the manufacturing
development necessary to satisfy regulatory requirements on a timeline
consistent with TKT's expectations or at all and to manufacture sufficient
quantities of TKT's products to satisfy both clinical trial requirements and
commercial demand, or to manufacture material at all, if approved; the
availability and extent of coverage from third party payors and the timing and
receipt of reimbursement approvals for the company's products; whether
competing products will reduce any market opportunity that may exist; results
of ongoing litigation and the risks of future litigation; whether competitors
will be able to limit access to markets in which TKT is attempting to sell
Dynepo, through legal maneuvering or otherwise; the need for cash; and other
factors set forth under the caption "Certain Factors That May Affect Future
Results" in the company's quarterly report on Form 10-Q filed August 9, 2004,
which is on file with the Securities and Exchange Commission and which factors
are incorporated herein by reference. While the company may elect to update
forward-looking statements at some point in the future, the company
specifically disclaims any obligation to do so, even if its expectations
change.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
Contacts:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 349-0271
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
- Financial Table to Follow-
Condensed Consolidated Statements of Operations (unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
(In thousands, except per share 2004 2003 2004 2003
amounts)
Product sales $19,479 $15,185 $54,920 $41,738
License and research revenues 79 1,533 239 1,577
19,558 16,718 55,159 43,315
Operating expenses:
Cost of goods sold 3,387 2,769 8,907 11,045
Research and development 23,527 17,895 65,674 55,730
Selling, general and
administrative 9,984 7,285 30,893 25,863
Restructuring charge 1,257 2,765 3,030 11,324
Intellectual property license
expense - - - 1,350
38,155 30,714 108,504 105,312
Loss from operations before
minority interest (18,597) (13,996) (53,345) (61,997)
Minority interest in net
(income)/loss of consolidated
subsidiary 23 31 55 (305)
Loss from operations after
minority interest (18,574) (13,965) (53,290) (62,302)
Net interest income 166 417 552 1,834
Loss on disposal of fixed assets (402) (5) (433) (50)
Net loss $(18,810) $(13,553) $(53,171) $(60,518)
Basic and diluted net loss per
share $(0.54) $(0.39) $(1.53) $(1.75)
Shares used to compute basic and
diluted net loss per share 34,728 34,567 34,665 34,551
Condensed Consolidated Balance Sheets (unaudited)
September 30, December 31,
(In thousands) 2004 2003
Cash and marketable securities $222,833 $180,947
Other current assets 46,932 44,392
Property and equipment, net 62,737 61,908
Other assets 4,846 1,922
Total assets $337,348 $289,169
Total current liabilities $27,939 $21,149
Long term liabilities 9,022 9,285
Long term debt 94,000 -
Minority interest 358 413
Total stockholders' equity 206,029 258,322
Total liabilities and stockholders'
equity $337,348 $289,169
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Justine E. Koenigsberg, Senior Director, Corporate
Communications, +1-617-349-0271, or Daniella M. Lutz, Corporate Communications
Manager, +1-617-349-0205, both of Transkaryotic Therapies, Inc.
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html